Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.48% | 38.02% | 44.43% | 45.47% | 39.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.33% | 49.68% | 63.35% | 54.04% | 52.32% |
| Operating Income | -31.33% | -49.68% | -63.35% | -54.04% | -52.32% |
| Income Before Tax | 41.30% | 68.11% | 77.20% | 141.57% | -250.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.30% | 68.11% | 77.20% | 141.57% | -250.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.30% | 68.11% | 77.20% | 141.57% | -250.31% |
| EBIT | -31.33% | -49.68% | -63.35% | -54.04% | -52.32% |
| EBITDA | -31.13% | -49.65% | -62.53% | -52.42% | -50.84% |
| EPS Basic | 50.17% | 73.62% | 80.82% | 135.82% | -53.76% |
| Normalized Basic EPS | 50.18% | 73.59% | 80.86% | 135.98% | -217.38% |
| EPS Diluted | 50.17% | 73.62% | 80.82% | 135.82% | -53.76% |
| Normalized Diluted EPS | 50.18% | 73.59% | 80.86% | 135.98% | -217.38% |
| Average Basic Shares Outstanding | 17.79% | 20.89% | 18.72% | 15.90% | 10.28% |
| Average Diluted Shares Outstanding | 17.79% | 20.89% | 18.72% | 15.90% | 10.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |